Behind the Scenes of Moderna's Latest Options Trends

Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna MRNA revealed 8 unusual trades.

Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $142,325, and 5 were calls, valued at $412,774.

Predicted Price Range

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $140.0 for Moderna over the recent three months.

Volume & Open Interest Trends

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $100.0 to $140.0 over the preceding 30 days.

Moderna 30-Day Option Volume & Interest Snapshot

Noteworthy Options Activity:

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance

Current Position of Moderna

• With a volume of 1,173,267, the price of MRNA is up 0.32% at $104.42.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 41 days.

What Analysts Are Saying About Moderna

In the last month, 3 experts released ratings on this stock with an average target price of $100.66666666666667.

• In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $125.
• Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Hold rating for Moderna, targeting a price of $91.
• An analyst from HSBC downgraded its action to Reduce with a price target of $86.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from Benzinga Pro.